期刊文献+

POR基因多态性与华法林维持剂量关系的研究 被引量:8

Associations of POR polymorphisms and warfarin stable maintenance dose in Han Chinese patients
下载PDF
导出
摘要 目的探讨POR基因多态性与华法林维持剂量的相关性。方法共纳入185例中国汉族人工心脏机械瓣膜置换术患者,采用Sequenom MassARRAYSystem检测VKORC1及POR相关SNPs,采用PCR-RFLP法检测CYP2C9*3基因型。采用ANOVA或t检验考察目的 SNPs与患者华法林维持剂量的关系。结果在CYP2C9*1*1携带者中,POR rs17685 T等位基因携带者(TT型和CT型)华法林维持剂量明显高于CC型携带者(3.50±1.07)mg·d-1vs(3.14±0.94)mg·d-1,P=0.03。在CYP2C9*1*1及VKORC1 rs9934438 GA/GG携带者中,POR rs17685 T等位基因携带者(TT型和CT型)的华法林维持剂量明显高于CC型携带者(4.76±0.90)mg·d-1vs(4.08±1.03)mg·d-1,P=0.04。未发现POR rs2868177与华法林维持剂量存在相关性。结论在中国汉族人工心脏机械瓣膜置换术患者中,POR rs17685 T突变与华法林剂量上调相关,该基因型检测将有助于指导华法林的临床合理应用。 Aim To explore the effect of genetic poly- morphisms of POR on the stable warfarin maintenance doses in Han Chinese patients receiving mechanical heart valve replacement. Methods The association between POR gene polymorphisms and warfarin doses of 185 Han Chinese patients were investigated through ANOVA or t test. SNPs of POR and VKORC1 were detected by Sequenom DNA MassArray genotyping method. CYP2C9 * 3 was genotyped by polymerase chain reaction-restriction fragment length polymorphism method (PCR-RFLP). Patients' clinical characteris- tics, INR value and daily dose were obtained from their medical records. Statistical analysis was performed by SPSS 21.0 software. Results No mutant carriers of POR rs17148944, POR rs56256515 and rs72553971 were found in this study. The genotype frequencies of other SNPs were in accordance with Hardy-Weinberg equilibrium. In the group of patients with CYP2C9 * 1 * 1, the mutant type carriers (T carriers ) of POR rs17685 had a significantly higher dose than CC carriers(3.50± 1.07) mg . d-1 vs (3.14 ±0.94) mg . d-1, p = 0. 03. Also, in the group of patients with CYP2C9* 1 * 1 and VKORC1 rs9934438 G allele carriers, the mutant type carriers (T carriers ) of POR rs17685 had a significantly higher dose than CC carriers(4.76±0.90) mg. d-1 vs (4.08 ±1.03) mg. d-1 ,p = 0. 04. No significant difference was found in different genotypes of POR rs2868177. Conclusion These results illustrate that POR rs17685 T carrier is closely associated with a higher warfarin maintenance dose, suggesting that this SNP is useful for clinical guidance of warfarin.
出处 《中国药理学通报》 CAS CSCD 北大核心 2014年第5期706-710,共5页 Chinese Pharmacological Bulletin
基金 "十二五"国家科技重大专项资助项目(No 2012ZX09506001-004) 国家自然科学基金资助项目(No 81170215 81102515 81173131 81320108027)
关键词 华法林 细胞色素P450 2C9 维生素K氧化还原酶复合体系1 细胞色素P450氧化还原酶POR 单核苷酸多态性 人工心脏机械瓣膜置换术 剂量个体差异 warfarin cytochrome P450 2C9 vitaminK epoxide reductase complex 1 cytochrome P450 oxidoreductase single nucleotide polymorphism artificial mechanical heart valve replacement inter-individual variation
  • 相关文献

参考文献2

二级参考文献10

  • 1程婕,杨凌.细胞色素P450氧化还原酶的研究进展[J].中国药理学通报,2006,22(2):129-133. 被引量:26
  • 2Wang, S. L.,Han, J. F.,He, X. Y.,Wang, X. R.,Hong, J. Y..Genetic variation of human cytochrome P450 reductase as a potential biomarker for mitomycin C-induced cytotoxicity[J].南京医科大学学报(自然科学版),2007,27(10):1171-1171. 被引量:1
  • 3Huang SW,Chen HS,Wang XQ,Huang L Xu DL Hu XJ. Validation of VKORC1 end CYP2C9 genotypes on interindividual warfarin maintenance dose:a prospective study in Chinese patients[J].PHARMACOGENETICS AND GENOMICS,2009,(03):226-234.doi:10.1097/FPC.0b013e328326e0c7.
  • 4Cen HJ,Zeng WT,Leng XY,Huang M Chen X Li JL. CYP4F2 rs2108622:a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement[J].British Journal of Clinical Pharmacology,2010,(02):234-240.
  • 5yoshizawa M,Hayashi H,Tashiro Y,Sakawa S Moriwaki H Akimoto T. Effect of VKORC1-1639 G 》 A polymorphism,body weight,age,and serum albumin alterations on warfarin response in Japanese patients[J].Thrombosis Research,2009,(02):161-166.doi:10.1016/j.thromres.2008.11.011.
  • 6Borgiani P,Ciccacci C,Forte V,Sirianni E Novelli L Bramanti P. CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population[J].Pharmacogenomics,2009,(02):261-266.doi:10.2217/14622416.10.2.261.
  • 7Cerveny L,Svecova L,Anzenbacherova E,Vrzal R Staud F Dvorak Z. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways[J].Drug Metabolism and Disposition,2007,(07):1032-1041.doi:10.1124/dmd.106.014456.
  • 8Lamba J,Lamba V,Schuetz E. Genetic variants of PXR (NR1I2) and CAR (NR1I3) and their implications in drug metabolism and pharmacogenetics[J].Current Drug Metabolism,2005,(04):369-383.doi:10.2174/1389200054633880.
  • 9Loparev VN,Cartas MA,Monken CE,Velpandi A Srinivasan A. An efficient and simple method of DNA extraction from whole blood and cell lines to identify infectious agents[J].Journal of Virological Methods,1991,(01):105-112.
  • 10Pautas E,Moreau C,Gouin-Thibault I,Golmard JL Mahé I Legendre C. Genetic factors (VKORC1,CYP2C9,EPHX1,and CYP4F2) are predictor variables for warfarin response in very elderly,frail inpatients[J].Clinical Pharmacology and Therapeutics,2010,(01):57-64.

共引文献19

同被引文献71

  • 1Johnson JA , Gong L , W h irl-C a m llo M , e t a l. C lin ic a lpharm acogenetics im plem entation consortium guidelinefo r CYP2C9 and VKORC1 genotypes and w a rfarin dosing [J]. Clin Pharmacol Ther, 2011, 90(4): 6 2 5 -9 .
  • 2Botton MR, Bandinelli E, Rohde LE, et al. Influence o f g e n etic, b io lo g ica l and pharm acological factors onw a rfarin dose in a Sothem B ra zilia n population o f Europeanancestry [J]. Br Clin Pharmacol, 2011, 7 2 (3 ):4 4 2 -5 0 .
  • 3Yang L, Ge W , Y u F, et a l. Im pact o f VKORC1 genepolym orphism on in te r -in d iv id u a l and in te re th n ic w arfarin dosage req u ire m e n t-a system atic review and metaanalysis [J]. Thromb Res, 2010, 125(4): e l5 9 -6 6 .
  • 4Yuan H Y , Chen JJ, Lee M T, et al. A novel fu n ction a lVKO RC1 prom oter polym orphism is associated w ith in ter-in d iv id u a l and in te r -e th n ic differences in w arfarinse n sitivity[J]. Hum Mol Genet, 2005, 14(13): 1745-51.
  • 5M iao L , Yang J, Huang C, et al. C on trib u tio n o f age,body w eight and CYP2C9 and VKORC1 genotype tothe anticoagulant response to w arfarin: proposal fo r anew dosing regim en in Chinese patients [J]. Eur J ClinPharmacol, 2007, 63(12): 1135-41.
  • 6F inkelm an BS, Gage BF, Johnson JA , e t a l. G eneticw arfarin dosing tables versus algorithm s [J]. J Am CollCardiol, 2011, 57(5): 6 1 2 -8 .
  • 7Danese E, M ontagnana M , Johnson JA , et a l. Im pact o fthe CYP4F2 p.V433M polym orphism on coum arin doserequirem ent: system atic review and m eta -analysis [J].Clin Pharamacol Ther, 2012, 92(6): 7 4 6 -5 6 .
  • 8Singh 0 , Sandanaraj E , Subram anian K , et a l. In flu enceo f CYP4F2 rs2108622 (V 433M ) on w a rfa rin doserequirem ent in A sian patients[J]. Drug Metab Pharmacokinet,2011, 26(2): 1 3 0 -6 .
  • 9R ieder M J, R einer A P , R e ttie A E . G lutam yl carboxylase(GGCX) tagSNPs have lim ite d u tility fo r p re d ictingw arfarin m aintenance dose [J]. J Thromb Haemost,2007, 5(11): 2 2 2 7-3 4 .
  • 10K im ura R , M iyashita K , Kokubo Y , et al. Genotypeso f vitam in K epoxide reductase, -g lu ta m y l carboxylase,and cytochrom e P450 2C9 as determ inants o f d a ilyw a rfa rin dose in Japanses patients [J]. Thromb Res,2007, 120(2): 1 8 1 -6 .

引证文献8

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部